Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B7 | P56937 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10273476 | 0.85 | HSD17B7 (0.66) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL15274285 | 0.79 | HSD17B7 (0.45) | HSD17B7MEN1KMT2A | |
| SCHEMBL10273977 | 0.78 | CYP19A1 (0.53) | MEN1KMT2A | |
| SCHEMBL12436567 | 0.74 | MEN1 (0.50) | HSD17B7MEN1KMT2ASRD5A2 | |
| SCHEMBL12436566 | 0.74 | MEN1 (0.50) | HSD17B7MEN1KMT2ASRD5A1SRD5A2 | |
| SCHEMBL10273975 | 0.72 | AR (0.59) | — | |
| SCHEMBL13630725 | 0.71 | MEN1 (0.74) | MEN1KMT2ASRD5A2 | |
| SCHEMBL10274435 | 0.71 | MEN1 (0.74) | MEN1KMT2ASRD5A2 | |
| SCHEMBL10273261 | 0.71 | MEN1 (0.74) | MEN1KMT2ASRD5A2 | |
| SCHEMBL10274340 | 0.71 | MEN1 (0.60) | MEN1KMT2ASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2660241-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| WO-2012083112-A2 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | CYP4A11, HSD17B11, CYP21A2 | HSD17B7 17/4885MEN1 2870/4885KMT2A 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.